I am a

Remsima®SC (infliximab) Website

Remsima®(infliximab) is the first biosimilar monoclonal antibody developed by Celltrion. Remsima® has been developed as intravenous and subcutaneous formulations to provide treatment options for patients with autoimmune disease. In Australia, only the subcutaneous format is marketed as Remsima®SC This website provides useful information about Remsima®SC.
If you are an Australian healthcare professional, please click the top icon. If you are a patient prescribed with Remsima®SC in Australia, please click the bottom icon. If you do not belong to either category, please contact Celltrion Healthcare, Australia for any appropriate information.